

17 December 2018

January 2019 Pharmaceutical Schedule Dispatch

This document is provided to pharmacists as an early notification of the changes to be announced in the **January 2019** Update to the Pharmaceutical Schedule. Please notify PHARMAC (enquiry@pharmac.govt.nz) if you want to change or remove your contact details.

New listings

- Calcium gluconate (Max Health) inj 10%, 10 ml ampoule – S29 and wastage claimable (p'code 2559315)
- Clozapine (Clozaril) tab 100 mg, 50 tab pack (p'code 2534878) and 100 tab pack (p'code 2534886) – Hospital pharmacy [HP4], safety medicine; prescriber may determine dispensing frequency
- Colecalciferol (Puria) oral liq 188 mcg per ml (7,500 iu per ml), 4.8 ml OP (P'code 2489783)
- Desferrioxamine mesilate (DBL Desferrioxamine Mesylate for Injection BP) inj 500 mg vial (p'code 461598)
- Domperidone (Pharmacy Health) tab 10 mg (p'code 2549093)
- Iron polymaltose (Ferrosig) inj 50 mg per ml, 2 ml ampoule (p'code 2135914)
- Medroxyprogesterone acetate (Provera S29) tab 2.5 mg (p'code 2536501) and 5 mg (p'code 378135) – see prescribing guidelines, S29 and wastage claimable
- Paediatric oral feed with fibre 1.5kcal/ml (Fortini Multi Fibre) liquid (unflavoured), 200 ml OP – Special Authority – Hospital pharmacy [HP3] (p'code 2558394)
- Paracetamol (Pharmacy Health (p'code 2558602) and Paracetamol Pharmacare (p'code 2559013)) tab 500 mg - blister pack – maximum of 300 tab per prescription; can be waived by endorsement, up to 30 tab available on a PSO
- Pharmacy services (BSF Entecavir Sandoz) brand switch fee – may only be claimed once per patient (p'code 2559420)
- Phenobarbitone sodium (Aspen) inj 200 mg per ml, 1 ml ampoule – Special Authority – Retail pharmacy, S29 and Wastage claimable (p'code 2550490)
- Varenicline tartrate (Varenicline Pfizer) tab 1 mg (p'code 2553163), and tab 0.5 mg x 11 and 1 mg x 42, 53 OP (p'code 2553155) – Special Authority – Retail pharmacy, varenicline will not be funded in amounts less than 4 weeks of treatment

Changes to restrictions, chemical names and presentations

- Aflibercept (Eylea) inj 40 mg per ml, 0.1 ml vial – amended Special Authority criteria
- Entecavir (Entecavir Sandoz) tab 0.5 mg – Brand Switch Fee payable
- Ferrous sulphate (Ferrograd) tab long-acting 325 mg (105 mg elemental) – reinstate stat dispensing
- Levodopa with carbidopa (Sinemet) tab 250 mg with carbidopa 25 mg – remove stat dispensing

- Medroxyprogesterone acetate (Provera and Provera S29) tab 2.5 mg and 5 mg – remove stat dispensing
- Metolazone (Metolazone and Zaroxlyn) tab 5 mg – Special Authority removed
- Phenytoin sodium (Dilantin) oral liq 30 mg per 5 ml – reinstate stat dispensing
- Propranolol (Cardinol LA) cap long-acting 160 mg – reinstate stat dispensing
- Varenicline tartrate tab 1 mg (Champix and Varenicline Pfizer), tab 0.5 mg x 11 and 1 mg x 14, 25 OP (Champix) and tab 0.5 mg x 11 and 1 mg x 42, 53 OP (Varenicline Pfizer) – amended note and Special Authority criteria

Increased subsidy

Chemical	Presentation	Fully subsidised brands
Chloramphenicol	Eye drops 0.5%, 10 ml OP	Chlorafast
Doxorubicin hydrochloride	Inj 1 mg for ECP	Baxter
Folic acid	Oral liq 50 mcg per ml, 25 ml OP	Biomed
Hydrocortisone butyrate	Oint 0.1%, 100 g OP Scalp lotn 0.1%, 100 ml OP Milky emul 0.1%, 100 ml OP	Locoid Locoid Crelo
Hydrocortisone with natamycin and neomycin	Crn 1% with natamycin 1% and neomycin sulphate 0.5%, 15 g OP Oint 1% with natamycin 1% and neomycin sulphate 0.5%, 15 g OP	Pimafucort
Hyoscine hydrobromide	Patch 1.5 mg	Scopoderm TTS
Oxaliplatin	Inj 1 mg for ECP	Baxter

Decreased subsidy

Chemical	Presentation	Fully subsidised brands	Partially subsidised brands
Azacitidine	Inj 1 mg for ECP	Baxter	
Dorzolamide with timolol	Eye drops 2% with timolol 0.5%, 5 ml OP	Dortimopt*	Arrow-Dortim
Methotrexate	Tab 2.5 mg and 5 mg	Trexate* (90 tab pack)	Trexate (30 and 50 tab pack)
Tamoxifen	Tab 20 mg	Genox Tamoxifen Sandoz*	

* no subsidy changes for these brands for 1 January 2019.